Comparison of the effect of Bisphosphonate on the prevention of type 2 diabetes among Osteopenic menopause prediabetes women and Referred to Isfahan Endocrine and Metabolism Research Center.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016101530309N1

Enrollment

Registered

2016-12-31

Start date

2016-03-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prediabetes. Impaired glucose tolerance, Menopausal and other perimenopausal disorders, Postmenopausal osteoporosis

Interventions

Intervention 1: Randomisation and blinding: Patients who are screened, signed the consent form, and fulfilled inclusion criteria and meet no exclusion criteria will be randomised using a sealed envelo

Treatment - Drugs

Randomisation and blinding: Patients who are screened, signed the consent form, and fulfilled inclusion criteria and meet no exclusion criteria will be randomised using a sealed envelope to either 70

Randomisation and blinding: Patients who are screened, signed the consent form, and fulfilled inclusion criteria and meet no exclusion criteria will be randomised using a sealed envelope to either 7

Eligibility

Sex/Gender

Female

Age

45 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion and exclusion criteria Inclusion criteria Prediabetes and menopause female patients who are resistant to insulin at age between 45 to 60 will be included if fulfilling the following two criteria: Osteopenia based on bone density measured by DAX machine Hologic 2008 model; Written consent by the patient to participate in the study obtained at the baseline Exclusion criteria Patients fulfilling any of the following criteria will be excluded from the study; Failure to use vitamin of OTC or trace element; Patients who do not like to continue with the study for any reason; Patients who take drugs that affect metabolism of glucose; The Osteoporotic patient; Patients with kidney failure problem.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
25 OH D3. Timepoint: Before and three months after the study. Method of measurement: Blood test.;Plasma glucose, Insulin Sensitivity and Insulin Resistance, HbA1C. Timepoint: Before and three months after the study. Method of measurement: Blood test.;Lipid Profile TG - Total Cholostrol LDL-HDL. Timepoint: Before and three months after the study. Method of measurement: Blood test.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Karimifard Maryam

Isfahan Endocrine and Metabolism Research Center, Isfahan University of Medical Sciences

Karimifardmaryam6@GMAIL.COM+98 913 290 9538

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026